

INVITATION
TO EXERCISE WARRANTS
OF SERIES TO 1
IN QLIFE



WORDS FROM THE CEO



VD för Qlife Holding AB

Qlife sees strong trends towards decentralized monitoring and diagnosis, without losing clinical precision, and professional analysis of data and treatment. Covid-19 is an excellent example that demonstrates the benefits of decentralized monitoring.

Decentralized monitoring makes patients' lives easier since they do not need to visit a hospital as often to take blood samples, and in addition monitoring can be adapted to individual needs to a greater extent. Decentralized monitoring plays an important role in the future distribution of resources in hospitals, clinics and care environments. As more patients are tested remotely, it will be possible to redistribute resources to patients who need to adjust their treatment plans.

To ensure the safety of patients and the acceptance from professionals, decentralized monitoring must be on par with what the central lab can offer when it comes to quality. Doctors, societies and patients will not accept less precise results as a basis for their treatment plans.

Our assessment is that there is a large group who for various reasons want to test their health parameters when the technology for decentralized monitoring is available. It can be about optimizing the performance of elite athletes, monitoring risk parameters or increasing knowledge about the impact of lifestyle changes on health.

That is why Qlife has developed the Egoo Health system. We currently offer our products to the clinical world, primarily with our Covid-19 virus test.

THE CONSUMER MARKET IS OUR LONG-TERM GOAL

Our long-term goal is to establish our system on the broad consumer market. The key to being able to move towards this market is to reach a production volume that is high enough and to ensure the quality of that level. An important part of our ongoing work is therefore to gradually increase the production volume of both capsules and Egoo.health units. We see the production of capsules as strategically important and are for that reason working to develop and maintain it in-house, while we follow an outsourcing strategy for the production of units.

THE DISTRIBUTION AGREEMENT – AN IMPORTANT STRATEGIC MILESTONE

Some weeks ago, we signed an exclusive European distribution agreement with Aidian Oy for the Egoo.Health device and Sars-CoV2 capsules for the clinical diagnostics market. Aidian Oy is a market leading In Vitro Diagnostics (IVD) company based in Finland. The agreement is exclusive for a number of European countries and the cooperation has already begun.

The agreement is a major milestone and builds on the long-term overall strategy of adding strategic partnerships for prioritized markets. We want to establish a strong base in the clinical diagnostics market before we begin processing the consumer market. We will do this by entering strategic partnerships with companies that already own their market, and the partnership with Aidian is part of this strategy.

The agreement with Aidian initially runs for three years with the option for both parties to be prolonged. The value of the contract for the first twelve months is estimated to be around SEK 40-50 million covering the Egoo.health unit and Sars-CoV-2 capsules.

IT IS INSPIRING TO BE A LISTED COMPANY

2020 was a very eventful year for Qlife, and the IPO was one of the biggest events. Being a public company means that you always have to be on your toes, and it gives a more professional view of the whole company. It is inspiring to be a listed company!

The start of 2021 has been successful for Qlife, as we reached two important milestones: CE marking of the Sars-Cov-2 test in the Egoo.Health system and a European distribution agreement with Aidian for the clinical market. We predict strong sales growth in 2021 and 2022, based on current and future distribution agreements plus a strong pipeline of new capsules.

MANY THANKS FOR YOUR SUPPORT!

I would like to thank all shareholders for your support during the year that Qlife now has been listed on the stock exchange, and I hope that you choose to continue to be part of our exciting development and future.

Thomas Warthoe
CEO, Qlife Holding AB



QLIFE IN BRIEF

Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement. Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fund Commission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).

Read more on Egoo.Health, Qlifeholding.com or follow us on LinkedIn.



TERMS FOR WARRANTS OF SERIES TO 1 IN BRIEF

There are 4,472,600 outstanding warrants of series TO 1. Holders of two (2) warrants of series TO 1 have the right through to subscribe for one (1) new share in Qlife Holding AB at a price of SEK 17.50 per share. Subscription with support of warrants of series TO 1 takes place during the period from 3 May 2021 up and including 31 May 2021. Subscription shall be made by immediate cash payment no later than on 31 May 2021.

AS WARRANT HOLDER YOU NEED TO DECIDE ON THE OFFER

– Here's how to exercise your warrants of series TO 1

In order for your warrants not to expire worthless, you must subscribe for new shares, with the support of warrants on 31 May 2021 at the latest, alternatively sell your warrants no later than on 27 May 2021.

YOU CAN HAVE YOUR WARRANTS REGISTERED IN TWO WAYS:

1. In a securities custody account with a bank or other nominee (for example, Avanza or Nordnet), in an investment savings account (Sw. Investeringsparkonto) or endowment account (Sw. Kapitalförsäkring). Your warrants are then nominee registered.
2. In a VP-account (a VP-account starts with three zeros). Your warrants are then directly registered.

IF YOUR WARRANTS ARE NOMINEE REGISTERED

Subscription and payment of new shares, by exercise of warrants, shall be made to the account-holding bank/nominee with which the warrants are registered. The subscription and payment shall be made in accordance with instructions from each such bank or nominee. Usually, the bank/nominee sends out a digital notice to the account holder, otherwise it is enough to log into the securities custody account from the first day in the exercise

period in order to get instructions on how to exercise warrants for subscription of new shares. If you do not find these instructions, please contact your bank or trustee. Please note that banks and other nominees may set different time limits for the last day for subscription, hence it is recommended to contact the account-holding bank/nominee early in the exercise period. Subscribed and paid for shares may be entered as "interim shares" or "IA" into your securities custody account until registration of the issue is completed with the Swedish Companies Registration Office, whereby interim shares will automatically be converted to ordinary shares in Qlife Holding AB.

IF YOUR WARRANTS ARE DIRECTLY REGISTERED

No VP-account statement will be sent out. Subscription of new shares, by exercise of warrants, shall be made by sending a completed subscription form to Nordic Issuing. In conjunction with sending the completed subscription form, payment must be made to Nordic Issuing in accordance with the payment details stated on the subscription form. The subscription form and folder are available at the respective websites of Qlife Holding AB (www.qlifeholding.com) and Nordic Issuing (www.nordic-issuing.se).

Completed subscription form and payment must be registered with Nordic Issuing no later than on 31 May 2021. Subscribed and paid for shares will be entered as "interim shares" or "IA" into your VP-account until registration of the issue is completed with the Swedish Companies Registration Office, whereby interim shares will automatically be converted to ordinary shares in Qlife Holding AB.

SUBSCRIPTION OVER EUR 15,000 WHERE APPLICABLE

If the subscription, made directly to Nordic Issuing, amounts to or exceeds EUR 15,000, questions on a money laundering form must be completed. The form is available on www.nordic-issuing.se and can be signed with BankID/NemID.

CONTACT

In case of any questions regarding warrants of series TO 1, please contact Nordic Issuing or Qlife Holding AB. Nordic Issuing is the issuing agent for Qlife Holding AB in connection with the exercise of warrants of series TO 1.

Nordic Issuing

Phone: +46 40 – 632 00 20

Email: info@nordic-issuing.se

Website: www.nordic-issuing.se